



Is Medical Evidence Enough?

How Evidence Based Medicine Affects Family Planning Providers: A Randomized Experiment in Jordan

Presenter: Marianne El-Khoury

Authors: Rebecca Thornton (University of Michigan), Marianne El-Khoury, Minki Chatterji, Maha Shadid, and Soonie Choi (Abt Associates)

13 April 2013



SHOPS is funded by the U.S. Agency for International Development. Abt Associates leads the project in collaboration with Banyan Global Jhpiego Marie Stopes International Monitor Group O'Hanlon Health Consulting

Background

- Biases and misconceptions held by health providers can adversely affect the delivery of quality health services.
- In Jordan, misconceptions toward family planning methods, especially hormone-based are common.
- Some studies find that using Evidence Based Medicine (EBM) approach helps reduce biases among providers.
- Research evidence disseminated through professional courses, workshops, educational outreach visits, or similar interventions

Objectives

- Study the impact of an EBM intervention in Jordan aimed to dispel misconceptions related to depot medroxy progesterone (DMPA), a 3-month hormonal injectable contraceptive on:
 - Providers' knowledge of DMPA and its side effects
 - Attitudes and perceived confidence towards DMPA
 - Clinical behaviors, such as discussion and prescription of DMPA

Methods

- Sample: 267 private health providers in two urban areas of Jordan, Amman and Zarqa
- Random assignment into Treatment (135) and Control (132), stratified by area and gender
- Baseline and endline surveys
- Overall response rates: 73% (baseline) and 85% (endline).



EBM DMPA Intervention

Treatment

- Providers invited to attend a roundtable seminar discussing research evidence on DMPA
- Providers participate in two educational visits to reinforce seminar messages on DMPA

Control

 Providers participate in two repeat educational visits to reinforce prior seminar messages on Combined Oral Contraceptives (COC)

Provider Characteristics and Baseline Equivalence

	Treatment	Control	Diff	(S.E.)
Provider Characteristics				
Female	0.68	0.69	-0.01	(0.06)
Yrs clinical experience	24.60	24.80	-0.20	(1.07)
Yrs clinical experience in FP	17.10	17.60	-0.50	(1.19)
Num patients per week	83.40	90.20	-6.80	(9.48)
Num FP patients per week	16.30	20.41	-4.11	(3.16)
Baseline Knowledge/Attitudes/Practices				
DMPA Knowledge Score (standardized)	0.08	0.03	0.05	(0.16)
Positive Attitude Score (standardized)	0.00	0.01	0.00	(0.15)
Availability of DMPA stock at clinic	0.20	0.23	-0.03	(0.06)
Times discussed DMPA with clients in past month	4.91	5.84	-0.93	(1.18)
Times prescribed DMPA in past month	1.85	2.43	-0.58	(0.55)

Estimation Strategy

Intent to treat (ITT) estimates using OLS:

•
$$Y_i = \alpha_1 + \beta_1 T_i + \varepsilon_{1i}$$
 Eq (1)

 Treatment on the treated (TOT) estimates using IV (2SLS):

•
$$Y_i = \alpha_2 + \beta_2 A C \widehat{TUAL} T_i + \varepsilon_{2i}$$
 Eq (2)


Where first stage is:

• $ACTUAL_T_i = \alpha_3 + \beta_3 T_i + \varepsilon_{3i}$ Eq (3)


Adherence to Intervention

	Treatment N=135	Control N=132	
Attended EBM seminar	0.452	0.015	
Received both educational visits on DMPA	0.763	0.000	
Received at least one educational visit on DMPA	0.852	0.000	
Attended seminar AND received both educational visits on DMPA	0.385	0.000	
Received at least one educational visit on COC	0.000	0.848	


Impact on Knowledge




Impact on Attitudes



Impact on Perceived Confidence



Impact on Clinical Practices



Treatment on Treated (IV)
Intention to Treat (OLS)

Summary / Discussion

• Overall, absence of large and significant impacts

- Some evidence of positive impact on willingness and comfort prescribing DMPA
- Providers less likely to identify two common and important side effects of DMPA
- Possible reasons:
 - High rate of no-shows to seminar; evidence of positive selection
 - Significant demand-side bias regarding DMPA
 - 'Light' intervention?
- Study limitations





Marianne El-Khoury Marianne_ElKhoury@abtassoc.com

www.shopsproject.org



SHOPS is funded by the U.S. Agency for International Development. Abt Associates leads the project in collaboration with Banyan Global Jhpiego Marie Stopes International Monitor Group O'Hanlon Health Consulting

Table A: Impact on Knowledge of DMPA

	Control group variable mean		Coefficient estimate on treatment (OLS)		Coefficient estimate on actual intervention (IV-2SLS)	
	Mean	S.D.	Mean	S.E.	Mean	S.E.
Dependent variable: Agree with -						
"Women who use DMPA less likely to suffer from anemia"	0.625	0.486	0.101	[0.062]	0.233	[0.143]
"Use of DMPA associated with weight gain"	0.384	0.489	-0.008	[0.064]	-0.018	[0.147]
"Women who use DMPA more likely to experience amenorrhea"	0.848	0.360	-0.053	[0.051]	-0.122	[0.117]
"Women who use DMPA more likely to experience spotting"	0.902	0.299	-0.081*	[0.045]	-0.186*	[0.108]
"I should not prescribe DMPA to nulliparous women who wish to delay childbirth"	0.563	0.498	0.027	[0.066]	0.063	[0.151]
"DMPA use is safe for most healthy women"	0.857	0.351	0.049	[0.043]	0.112	[0.097]
Dependent variable: Disagree with -						
"Women are at a higher risk of ectopic pregnancy if they use DMPA long term"	0.839	0.369	0.015	[0.048]	0.035	[0.109]
"DMPA use is associated with an increased incidence of breast cancer"	0.759	0.430	0.070	[0.054]	0.161	[0.124]
"After two years of continuous use of DMPA, women should give their body a rest"	0.259	0.440	0.023	[0.059]	0.053	[0.134]
Knowledge score effect (standardized)	0.000	1.000	0.061	0.129	0.141	0.294

Table B: Impact on Attitudes andPerceived Confidence in DMPA

Dependent variable		l group e mean	Coefficient estimate on treatment (OLS)		Coefficient estimate on actual intervention (IV-2SLS)	
	Mean	S.D.	Mean	S.E.	Mean	S.E.
Agree with: "For some women, amenorrhea can be beneficial or desired"	0.670	0.472	-0.029	[0.063]	-0.066	[0.145]
Agree with: "I would like to obtain more DMPA info"	0.839	0.369	-0.044	[0.051]	-0.102	[0.118]
Agree with: "If women in Jordan had more information about DMPA, more women might accept its use"	0.759	0.430	0.044	[0.055]	0.102	[0.125]
Agree with: "I would have no hesitations to recommend DMPA to a healthy woman who wanted to use this method"	0.830	0.377	0.076*	[0.045]	0.173*	[0.103]
Attitude score effect (standardized)	0.000	1.000	0.046	0.131	0.106	0.297
Feel knowledgeable about DMPA [0-10]	7.866	1.882	0.202	[0.260]	0.464	[0.589]
Feel confident discussing DMPA [0-10]	7.793	2.534	0.147	[0.340]	0.338	[0.775]
Feel comfortable prescribing DMPA [0-10]	5.955	3.198	0.917**	[0.424]	2.103**	[0.990]
Perceived Confidence Score effect (standardized)	0.000	1.000	0.188	0.137	0.464	0.589

Table C: Impact on Reported Practices

Dependent variable	Control group variable mean		Coefficient estimate on treatment (OLS)		Coefficient estimate on actual intervention (IV-2SLS)	
	Mean	S.D.	Mean	S.E.	Mean	S.E.
Availability of DMPA stock at clinic	0.268	0.445	-0.088	[0.055]	-0.203	[0.131]
Number of times discussed DMPA with clients in past month	12.28	57.53	-3.67	[5.71]	-8.51	[13.25]
Number of times prescribed DMPA in past month	2.80	5.29	0.77	[0.70]	1.78	[1.63]

Table D: Baseline Statistics, by Seminar Attendance

	Seminar = 1	Seminar =0	Difference (1) - (2)	
		Semmar =0	Mean	SE
	(1)	(2)	(3)	
Baseline Knowledge on DMPA				
Disagree: Higher risk of ectopic pregnancy	0.729	0.750	-0.021	0.073
Disagree: Higher risk of breast cancer	0.875	0.800	0.075	0.064
Agree: Anemia less likely	0.771	0.607	0.164	0.079**
Disagree: After two years DMPA, should give body rest	0.521	0.312	0.209	0.079***
Agree: Weight gain more likely	0.437	0.389	0.048	0.082
Agree: Should not prescribe if nulliparous and wants to delay	0.255	0.243	0.012	0.073
Agree: Safe for most healthy women	0.937	0.860	0.077	0.054
Average Knowledge Score (normalized)	0.289	-0.032	0.321	0.167*
Baseline Attitudes				
Agree: for some, amenorrhea can be beneficial	0.812	0.657	0.155	0.076**
Agree: If more had info, more might use DMPA	0.704	0.746	-0.042	0.077
Agree: No hesitations to prescribe DMPA	0.854	0.792	0.063	0.066
Agree: I would like more info on DMPA	0.959	0.914	0.045	0.043
Average Positive Attitude Score (normalized)	0.162	-0.040	0.202	0.169
Baseline Practices				
Availability of DMPA stock at clinic	0.239	0.212	0.028	0.071
Average # times discussed DMPA with clients in past month	5.200	5.482	-0.282	1.270
Average # times prescribed DMPA in past month	1.950	2.270	-0.320	0.612
Sample (N)	63	204		